Navigation Links
Obio Pharmaceutical Announces Product Growth Strategy
Date:2/18/2009

n antiviral drug candidate -- TG21 that could tackle avian and human influenza virus. Thanks to the US Food and Drug Administration (FDA) and EU European Medicines Agency (EMA) previous approval of the active ingredient of TG21 as an orphan drug, its safety profile is assured. As cases of resistance to the mainstream medical intervention -- Tamiflu are on the rise, TG21 can be considered an alternative drug preparing for possible pandemic threat. TG21 works on a different mechanism to that of both Tamiflu and Relenza, which are Neuraminidase Inhibitors. TG21 does not work on the same target so the influenza virus is less likely to develop resistance to TG21.

A US Patent Attorney has prepared a patentability report for TG21, application of patents has also been filed on TG21 and pending approval. As a drug research and discovery company, Obio is in process to apply for a fast track mode to accelerate drug registration given the needs of effective treatment for lethal influenza viruses are unmet, and actively negotiating partnership with large pharmaceuticals companies to produce the drug.

Apart from the aforementioned drug candidates, the Company continues to push research of its candidates in life-style and Parkinson disease arenas. The Company believes that its research focus will achieve the Company vision to research and develop novel drugs, and bring them into the market through co-development with other prestigious pharmaceutical companies.

Dr. Bill Chan, Director and Chief Technical Officer of the Company, said, "All the drug candidates on hand should be able to capture the attention from the pharmaceutical industries. Some of them have high chance to become blockbuster drugs after analyzing the market demand. Now, Obio holds all the aces and ready to launch its products; the growth strategy in launching the blockbuster drugs together with other pharmaceutical companies will certainly accelerate
'/>"/>

SOURCE Obio Pharmaceutical Holdings Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
2. Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan
3. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
4. TechniKroms Biopharmaceutical Equipment Operations to be Integrated With Asahi Kasei Medical
5. Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009
6. Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)
7. Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results
8. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
9. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
10. Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix
11. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Wednesday, February 18, 2009 at 8:45 a.m. EST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 /PRNewswire/ ... company advancing patient care in critical areas, announced the ... of common stock, and warrants to purchase up to ... offering price of $4.00 per share and $.01 per ... of $5.00, are exercisable immediately, and expire 5 years ...
(Date:12/24/2014)... Earlier this year in a June 24 ... the Adult Stem Cell Technology Center, LLC ( ASCTC ... appreciated unique property of adult tissue stem cells. ... in the Past, Important for the Future,” embodied the ... gave the address at the 4th World Congress on ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. ... American Society for Reproductive Medicine (ASRM), a leading professional ... medicine. In his new role as treasurer, Dr. ... and will have a voice in furthering the mission ... ASRM since 1984 when he joined while conducting fellowship ...
(Date:12/24/2014)... December 23, 2014 PharmaBoardroom,s ... out today and available for free download , digs ... change and growth in the sector today. One ... successes has been in developing a homegrown pharmaceutical manufacturing base, ... production still remains some way off. A cursory comparison with ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3
... MADISON Wisconsins law enforcement agencies are slated to begin ... identify criminals. The training, sponsored by the Oshkosh Police Department, ... system allows photo-like images of suspects to be created quickly ... facial features, hairstyles, hats, scars and tattoos. , ,FACES, which ...
... is available for technology companies as part of a ... Technologys Advanced Technology Program . All U.S.-owned, for-profit ... all technology areas may be submitted. , ,The awards ... capital for visionary, high-technology businesses that will have an ...
... Friday designed to promote capital investment and technological entrepreneurship ... legislation, SB 261 , was only one of ... R-Brookfield, to hit the Assembly floor this session. Its ... Capital Companies Program, (WISCAP) is a revised version of ...
Cached Biology Technology:Wisconsin Assembly passes capital investment bill, revised CAPCO program not presented 2Wisconsin Assembly passes capital investment bill, revised CAPCO program not presented 3
(Date:12/11/2014)... Dec. 10, 2014  Data Sciences International (DSI), ... released a new series of digital telemetry implants ... researchers. M series, part of the PhysioTel™ Digital ... best possible physiologic data when incorporating functional endpoints ... endpoints to toxicology studies has evolved from short ...
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ... the ultimate driver in long-term mass consumer adoption of ...
(Date:12/10/2014)... , Dec. 9, 2014 CIE San ... catalyst that provides the connective tissue that enhances care ... them to easily share client-level information; earned a second ... expand to organizations serving seniors aging in community and; ... partner on December 11 th 4-6p. ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... the October 2011 issue of Experimental Biology and ... Medical Center led by Stephen Tsang, MD, Ph.D have ... model for retinitis pigmentosa (RP) using novel bipartite gene ... by progressive degeneration of rod photoreceptors (which mediate night ...
... The carbon dioxide we exhale and the odors our skins ... hunt for human hosts to bite and spread diseases such ... at the University of California, Riverside have now performed experiments ... that transmit yellow fever and dengue -- respond to plumes ...
... Irvine, Calif., Sept. 30, 2011 A glucosamine-like dietary ... sclerosis, according to a UC Irvine study. UCI,s ... oral N-acetylglucosamine (GlcNAc), which is similar to but more ... and function of abnormal T-cells that in MS incorrectly ...
Cached Biology News:Cell-specific mechanism-based gene therapy approach to treat retinitis pigmentosa 2Cell-specific mechanism-based gene therapy approach to treat retinitis pigmentosa 3Flight patterns reveal how mosquitoes find hosts to transmit deadly diseases 2Glucosamine-like supplement suppresses multiple sclerosis attacks 2
... Ether 30% concentration in ... Surfactant. Clear Solution. Recommended ... 1 mL of 30% ... to 400 mL of ...
... between P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) ... the lumenal surface of endothelial cells at ... primary role of PSGL-1 in mediating the ... well documented.MAB4092 completely blocks recognition of PSGL-1 ...
Mitotic Kinesin-Like Protein 1 (MKLP-1, KNSL5)...
MMP-1/8 (H-300)...
Biology Products: